In this module we summarize effective principles for OUD treatment, based on those developed for general substance use treatment by several organizations.1-3 These principles inform the approach taken throughout the Playbook and should be helpful to keep in mind as you implement treatment for OUD, regardless of whether your practice only provides MOUD or is also able to offer additional services.
- Don't have a single fixed treatment design that every patient with OUD is expected to fit within.
- Don't forget to identify what is important to the individual patient and use motivational interviewing principles to encourage them to begin and remain in treatment.
- Don't expect all patients to progress at the same rate or treat them disrespectfully if they stumble and return to substance use.
Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition) (PDF - 1.2MB)
A resource for health care providers, family members, and other stakeholders serving individuals with substance use disorders.
Shatterproof National Principles of Care
1. American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. Journal of Addiction Medicine. 2020;14(2S):1-91. doi:10.1097/ADM.0000000000000633
2. University of Wisconsin-Madison. Buprenorphine Implementation Toolkit 2020. NIATx. 2020. Accessed April 21, 2025. https://niatx.wisc.edu/buprenorphineimplementationtoolkit2020/
3. Shatterproof. Shatterproof National Principles of Care. 2025. Accessed April 24, 2025. https://www.shatterproof.org/shatterproof-national-principles-care
4. U.S. Preventive Services Task Force. Unhealthy Drug Use: Screening. U.S. Preventive Services Task Force. 2020. Accessed May 4, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening
5. Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. SAMHSA Library. 2021. Accessed April 7, 2025. https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder/pep21-02-01-002
6. Substance Abuse and Mental Health Services Administration. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). SAMHSA. February 5, 2021. Accessed April 21, 2025. https://www.samhsa.gov/resource/ebp/principles-drug-addiction-treatment-research-based-guide-third-edition
7. Monroe SC, Radke AK. Opioid withdrawal: role in addiction and neural mechanisms. Psychopharmacology (Berl). 2023;240(7):1417-1433. doi:10.1007/s00213-023-06370-2
8. Crouch TB, Donovan E, Smith WR, Barth K, Becker WC, Svikis D. Patient Motivation to Reduce or Discontinue Opioids for Chronic Pain: Self-Efficacy, Barriers, and Readiness to Change. Clin J Pain. 2024;40(1):18-25. doi:10.1097/AJP.0000000000001167
9. Lee CS, Rosales R, Stein MD, et al. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients. Am J Addict. 2019;28(5):409-412. doi:10.1111/ajad.12925
10. Cunninghma C, Fishman M. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opiod Use. American Society of Addiction Medicine; 2015. Accessed April 21, 2025. https://www.samhsa.gov/sites/default/files/sites/default/files/opioid-addiction-asam-use-of-medications-in-treatment.pdf?utm_source=chatgpt.com
11. National Institute on Drug Abuse. The Science of Drug Use and Addiction: The Basics. NIDA Archives. 2024. Accessed May 4, 2025. https://archives.nida.nih.gov/publications/media-guide/science-drug-use-addiction-basics
12. National Institute on Drug Abuse. Treatment and Recovery. NIDA. 2020. Accessed May 4, 2025. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
13. Danovitch I, Freedman KI, Frost MP, et al. Engagement and Retention of Nonabstinent Patients in Substance Use Treatment. American Society of Addiction Medicine
14. Harris RA, Kearney M, Keddem S, et al. Organization of primary care and early MOUD discontinuation. Addiction Science & Clinical Practice. 2024;19(1):96. doi:10.1186/s13722-024-00527-w
15. Glanz JM, Binswanger IA, Clarke CL, et al. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment. Addiction. 2023;118(1):97-107. doi:10.1111/add.15998
16. Jiang X, GuyJr GP, Dever JA, et al. Association Between Length of Buprenorphine or Methadone Use and Nonprescribed Opioid Use Among Individuals with Opioid Use Disorder: A Cohort Study. Substance Abuse. 2025;46(2):266-279. doi:10.1177/29767342241266038
17. Burns M, Tang L, Chang CCH, et al. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study. Addiction. 2022;117(12):3079-3088. doi:10.1111/add.15959
18. Hasan MM, Noor-E-Alam M, Shi J, Young LD, Young GJ. Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population. Am J Drug Alcohol Abuse. 2022;48(4):481-491. doi:10.1080/00952990.2022.2065638
19. Leshner AI, Mancher M, eds. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019. doi:10.17226/25310
20. Martin SA, Chiodo LM, Bosse JD, Wilson A. The Next Stage of Buprenorphine Care for Opioid Use Disorder. Ann Intern Med. 2018;169(9):628-635. doi:10.7326/M18-1652
21. Almeida A, Conway M, Grelotti DJ, Gupta A, Frank D, Bórquez A. Medication experiences in the treatment of opioid use disorders: Insights from Reddit. Addiction. 2025;120(8):1610-1622. doi:10.1111/add.70022
22. Zhu T, Noor-E-Alam Md, Hasan MM, Young LD, Young GJ. Counseling as a complement to buprenorphine treatment for opioid use disorder: A retrospective observational study of patient outcomes. J Subst Use Addict Treat. 2025;175:209719. doi:10.1016/j.josat.2025.209719
